BDPC

BDPC (systematic name 4-(4-bromophenyl)-4-(dimethylamino)-1-(2-phenylethyl)cyclohexanol) is a potent narcotic analgesic with a distinctive arylcyclohexylamine chemical structure. It was developed by the team led by Prof. Helmut Ortmanns and Dr. Juergen Sauer of the pharmaceutical company Grünenthal in the late 1970s and early 1980s.

Chemistry

BDPC is a cyclohexanol derivative and is structurally related to other drugs of the arylcyclohexylamine class, such as phencyclidine (PCP) and ketamine. It is specifically a 4-bromo derivative of 2-(2,6-dimethylphenylamino)-2-(2-phenylethyl)cyclohexan-1-one.

Pharmacology

BDPC acts as a mu-opioid receptor agonist. It is one of the most potent opioid agonists known, approximately 504 times more potent than morphine in animal models.

Medical Use

BDPC has never been used in humans, but would be expected to produce effects similar to those of other potent opioid agonists, including strong analgesia, sedation, euphoria, constipation, itching and respiratory depression which could be harmful or fatal.

Legal Status

BDPC is not currently listed in any schedule of the United Nations Drug Conventions, but it may be covered under the analogue act in some countries such as the United States or Australia.

See Also

• Opioid
• Analgesic
• Phencyclidine
• Ketamine

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian